ADM and small cell lung carcinoma: Future studies are warranted to further elucidate the role of ADM and ST2 as well as other candidate CV biomarkers as guidance for cardiotoxic anti-tumoral therapy in patients with SCLC, perhaps even more importantly with regard to the emergence of immunotherapy.